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ABSTRACT    
 
BACKGROUND: Despite the shift in antiretroviral therapy (ARVs) 
eligibility cascade from CD4 ≤ 200 to CD4 ≤ 350 to CD4 ≤ 500 
mm
3
, HIV related morbidity and mortality continue to escalate 
annually, as do HIV infections. The new paradigm of treatment for 
all HIV positives individual   irrespective of CD4 count may 
significantly reduce HIV and related illnesses. The author assumes 
that all HIV infected partners should be eligible for HIV treatment 
and care, irrespective of CD4 count. A second assumption is that 
high risk HIV negative partners have free access to continuum of 
HIV pre-exposure prophylaxis (PrEP), post exposure prophylaxis 
(PEP) and other prevention packages.   
METHODS: A literature review search was used to extract 
evidence-based ARVs-HIV treatment and prevention interventions 
among HIV positives and high risk partners respectively. Only 
articles published in English and indexed in journal nuclei were 
used for the study. The information was used to nurture 
understanding of HIV treatment and prevention approaches as 
well as HIV incidence multiplier effect among HIV serodiscordant 
partners. The imputed HIV incident reference was assumed at 1.2 
per 100 person-years (2). This was based on the imputation that 
retention in care, adherence and other predetermined factors are 
functions of an effective health care delivery system.    
RESULT: The model showed a reduced HIV transmission from 1.2 
per 100 person-years to 1.032 per 100 person-years in 6 months. 
The average threshold period of HIV suppressed partners on ARVs 
to an undetectable level. The combined multiplier protective-effect 
probability of transmitting HIV from HIV positive partners on 
ARVs-suppressed viremic load to HIV negative partners on 
PrEP/PEP-prevention was detected at 86% 
CONCLUSION: The model showed a significant reduction in HIV 
incidence. Placing serodiscordant sexual partners in HIV 
treatment and prevention plays a significant role in reducing and 
controlling HIV infection. Therefore, the policy of enrolling all 
HIV positives irrespective of CD4 count on ARVs and high risk 
partners on prevention if adopted and sustained may underpin 
reduction and control of HIV genotype and HIV related morbidity, 
mortality and opportunistic infections.  
KEYWORDS: HIV, test and treat, linkage to care, prevention, 
incidence  
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HIV infection is the most widely sensitized, 
researched, implemented and costly pandemic 
intervention program the world is still struggling 
to contain. According to estimates by UNAIDS, 
31.1 billion US Dollars is projected to be spent by 
2020  and US$ 29.3 billion by 2030 to contain 
HIV and related morbidities and mortalities (6). 
The fatality rate is over 30 million people (7), and 
currently over 36 million people are living with 
the virus with an estimated 17 million accessing 
ARVs globally(8).  
Since the introduction of ARVs eligibility 
from CD4 ≤ 200 to CD4 ≤ 350 and to CD4 ≤ 500 
mm
3
 cascade, HIV new infections and related 
disease burden continued to escalate annually. 
With the introduction of combination prevention 
packages of HIV testing services (HTS) and 
ARVs treatment, coupled with sustained 
partnership with local and international 
stakeholders in containing the epidemic, new HIV 
infections have dropped by 35% since 2000, 
including HIV related mortality by 42% (6). 
Evidence-based researches reveal continuum of 
HTS, HIV treatment coverage and ARVs 
prevention to play a significant role in reducing 
HIV-viremic transmission and acquisition (1-3).   
Furthermore, active social mobilization 
engagement and empowerment of local 
communities are additional behavioural change 
communications that have enhanced acceptability 
and uptake of HIV prevention and health seeking 
behaviour (9). Others include the utilization of 
sexual reproductive health (SRH) services and 
right to venerable population such as adolescents 
(10-12, 35). According to Williams et al (7), 
social, behavioural, biomedical and community 
level testing have enhanced and improved 
acceptability and uptake of health services. These 
evidence-based interventions have played a 
significant role in reducing HIV incidences in sub-
Saharan Africa.  
By engaging all partners in the algorithm of 
HTS and treatment cascade irrespective of CD4 
count, retention in care, adherence and vigorous, 
active prevention strategies are essential 
innovative strategies in achieving the 90-90-90 
HIV objectives especially in high risk vulnerable 
settings (13,14) including key populations (12) 
and adolescents-girls (11,12). In addition, the 
current concept of enrolling all those who test 
positive for HIV on treatment and linkage to care 
irrespective of CD4 count and active access to 
PrEP, PEP, condoms, lubes and treatment of other 
sexually transmitted infections (STIs)  have 
emerged as a new expansion of care and 
prevention. The implementation may account for 
HIV genotype containment globally. The author 
therefore assumed that all HIV infected partners 
should be eligible for HIV treatment and care, 
irrespective of CD4 count. A second assumption is 
that high risk HIV negative partners have free 
access to continuum of PrEP, PEP and other 
prevention packages because they are in HIV 
serodiscordant relationship. The proposed model 
describes the HIV incidences with the assumption 
that all HIV infected partners are eligible to ARVs 
treatment and linkage to care irrespective of CD4 
count. The trajectory is based on the assumption 
that HTS and ARVs quality in routine health 




A literature review search design was used to 
extract evidence-based high quality ARVs-HIV 
treatment and prevention interventions among 
HIV positives and high risk partners. The articles 
included in the study were those published in 
English and  provided clear description of HIV 
rate due to ARVs treatment (96%) (1-3)  and 
prevention (PrEP and PEP) interventions (90%) 
(4).  
Keywords such as “antiretroviral treatment 
and viral load reduction/suppression”, "HIV 
treatment and prevention among serodiscordant 
partners " and “PrEP, PEP amongst HIV negative 
partners” were used for the search.  
Serodiscordant relationship (partner) was defined 
as one being partner HIV positive and the other 
being  HIV negative and likely to acquire HIV 
from the HIV positive partner. The following 
indexing journal nuclei were used for the search: 
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Cochrane Library, PubMed, MeSH PsycInfo, 
Scopus and Google Scholar, Embase and Global 
Health. The synthesised evidence-base 
interventions were used to nurture understanding 
of HIV treatment and prevention approaches. This 
was based on ARVs-viral load suppression among 
HIV positives and HIV prevention amongst 
sexually active high risk partners on either PrEP or 
PEP. The imputed HIV incident in the study was 
assumed at 1.2 per 100 person-years (2).  
This assumption was based on the fact that 
retention in care, adherence and other 
predetermined factors are functions of an effective 
health care delivery system. The predetermined 
factors include arrays of behavioural, socio-
economic and structural factors related to HIV 
acquisition and transmission which were 
highlighted as constant variables in the model 
(28). Inclusive were factors such as mobility and 
migration, cultural practices (circumcisions) and 
educational status, early sexual debut and sexual 
violence (15). Other constants included were 
alcohol and drug use, condom use (13,14), and 
mother to child transmission of HIV (MTCT) 
during pregnancy and post natal care (16).  
 
The model HIV treatment and preventions 
approaches: The study estimated HIV 
transmission in all suppressed viremic partners on 
ARVs to HIV negative partners at approximately 
4% (1-3) and HIV acquisition from HIV positive 
partners to HIV negative partners on PrEP and 
PEP at approximately 10% (4,7). This model 
therefore accounted for 2 cascades: treatment 
cascade (HIV positive-ARV treatment) and 
prevention cascade (HIV Negative-PreP and PEP), 
while retention in care, adherence, STIs treatment 
and other variables are held constant and imputed 
as a function of an effective health care delivery 
quality. Entry to the model were HIV positive 
individuals on ARVs care and PMTCT 
programme. Linkage to care cascade are all who 
test positive for HIV, irrespective of CD4 count 
and whether they are on HIV treatment or not. 
These were called HIV transmission partners, 
while those in the prevention arm are high 
risk/exposed HIV negative partners’ accessing 
PrEP or PEP. These were termed HIV acquisition 
partners. 
 
Estimating HIV incident using 100% test and 
treat, linkage to care irrespective of CD4 count 
and prevention strategies: Antiretrovirals 
(ARVs) have been tested, proved and defined as a 
critical pointer in controlling HIV replication, 
reduction in viremic load, transmission and 
maintaining of health quality (1-3). There are 
several predictor factors associated with HIV 
treatment and ARVs administration including 
ARVs-partner specific properties, the virus 
characteristics, patient-specific variables, 
environmental variables as well as patient provider 
relationships (19). In the model, these variables 
were imputed as constant although they do play a 
significant role in HIV transmission and 
acquisition.  
Note that the prime entries into the model are: 
sustained ARVs or PMTCT and linkage to care all 
HIV positive partners irrespective of CD4 count 
and free access to HIV preventions (PrEP/PEP) 
sexually high risk/exposed HIV negative partners.  
Using the basic reproduction number (R0), 
which is the expected number of secondary new 
HIV infections from an infected partner to a 
completely HIV negative population as defined in 
equation 1.  The model uses this to highlight the 
transmission of HIV from an infected partner to 
susceptible partners.  
R0 =T.C.D …………………equation 1. 
Where T = Transmissibility probability of 
infection given contact between a susceptible and 
HIV infected partner. C = Average rate of contact 
between susceptible and HIV infected partner, D = 
Duration of infectiousness. 
The model considers retention in care, 
adherence and other variables as constants. This 
implies that infected HIV partners who are fully 
on ARVs or PMTCT compliance have low 
undetectable viremic load and  a 96% chance of 
not transmitting HIV to HIV negative partners. 
While those on HIV preventions such as PrEP and 
PEP have a 90% chance of not acquiring HIV 
from HIV positive partners during sexual 
intercourse.  Therefore, if R0 can be sustained and 
substantially reduce to less than 1 due to viral load 
suppression by ARVs. This may significantly 
reduce new HIV infections. 
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Based on equation 1 and other sources, we 
assumed the probability of all virally suppressed 
HIV positive partners on ARVs, transmission of 
HIV to susceptible partners at 96% (p= 0.96) (1-
3)……………………................... Equation 2 
Also the probability of sexually active HIV 
negative partner on PrEP or PEP acquiring HIV 
from infected partner is estimated at 90% (q = 0.9) 
(4, 5) ……………Equation 3. 
Therefore, the multiplication effect of 
transmission and acquiring probability from 
equations 2 & 3 = p x q = (0.96 x 0.9) = 0.86 
(86%)……………Equation 4. 
This implies that the combined probability 
effect of transmitting HIV from HIV positive 
partners on ARVs-suppressed viremic load to HIV 
negative partners and HIV negative partners on 
PrEP/PEP-prevention is approximately 0.86 
equating to 86% (4,7). In addition, according to a 
study by Cohen et al (2), the incident rate among 
serodiscordant stable HIV relationship where one 
partner is fully on ARVs is estimated at 1.2 per 
100 person-years. Mathematically, the combined 
probability of transmitting and acquiring of HIV at 
incident rate of 1.2 per 100 person-years will be 
estimated at 1.032 (0.86 x 1.2) per 100 person-
years provided other factors are held constant 
including ARVs-resistant HIV strains.  
Studies show that retention and adherence in 
ARVs for 6 months account for viremic 
suppression to undetectable level in plasma (20). 
This implies that retention in care and adherence 
in ARVs treatment and prevention for 6 months 
can halt HIV transmission and acquisition among 
serodiscordant partners during sexual intercourse 
by 86%. This can significantly reduce HIV 
incidences including morbidity and mortality of 
HIV related infections. Figure 1 below depicts a 
simple algorithm model of HIV transmission and 
acquisition in a disproportionally high risk and 
exposed serodiscordant partners.  
 
Figure 1: HIV ART, prevention and incidence cascade 
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According to findings by Cohen et al (2), HIV 
transmission rate among serodiscordant partners 
eligible to CD4 count and ARVs-treatment is 
estimated at 1.2 per 100 person-years. The average 
threshold period of HIV suppressed partners on 
ARVs to an undetectable level. While the adoption 
of test and treat model among serodiscordant 
partners irrespective of CD4 count and ARVs-
treatment reduces the HIV incidence from 1.2 per 
100 person-years to 1.032 per 100 person-years. 
The combined multiplier protective-effect 
probability of transmitting HIV from HIV positive 
partners on ARVs-suppressed viremic load to HIV 
negative partners on PrEP/PEP-prevention was 




Continuum of HIV counselling and testing 
(HCT) and couple voluntary counselling and 
testing (CVCT): Without HCT/CVCT, the 
probability of estimating the burden of the disease 
and accounting for the 90-90-90 cascade will be a 
failure. HIV counselling and testing is the prime 
gateway and entry point into HIV treatment, care 
and prevention (17). Although operational and 
continuous imperative logistics including 
shortages of HCT consumables and health care 
providers, skilled-competent counsellors and 
community health workers may be hindering 
sustain acceptability, uptake and adoption of 
HCT/CVCT.  The 90-90-90 sustained HCT/CVCT 
acceptability, uptake and adoption require a 
robust-decentralized heath service delivery 
system. This includes capacity development, 
support structures, community decentralization of 
HCT and the integration of community HCT 
services into the national delivery HCT testing and 
treatment grid. The downstream strengthening of 
HCT/CVCT services plays an essential role in 
bridging positive changes and sexual behaviour of 
other STIs, HIV treatment and care, retention and 
adherence. Other hindering variables include 
partner disclosure, stigma and discrimination, 
positive living and positive prevention, 
psychosocial support, mental health and HIV 
related opportunistic infections treatment as well 
as tuberculosis (TB). The current HTS has 
incorporated point-of care (POC) testing such as 
POC-CD4 and POC-creatinine and on-site ARVs 
initiation and linkage to care and services (29). 
This is accompanied by direct communication and 
collaboration with local clinics where partners can 
receive further referral and access to drugs (18). 
Continuum of HIV treatment and prevention 
cascade: To fulfil the 90-90-90 HIV test, treat, 
and viral load suppression approach irrespective of 
CD4 count especially in sub-Saharan Africa, 
countries such as Namibia and South Africa are 
already implementing the program to all HIV 
positives and serodiscordant partners. The 
recommendations are based on real time evidence-
base findings that people who start ARV treatment 
earlier get better health outcomes and are likely to 
reduce HIV transmission in serodicordant 
relationship (1-3,33). HIV-positive partners on 
ARVs with suppressed viral load to undetectable 
level have more than 96% chances of  not 
transmitting the virus to their HIV negative sexual 
partners (1-3,33) while those on PrEP and PEP 
have more than 90% chances of not acquiring HIV 
from HIV positive partners (4). The mathematical 
modelling from studies showed a combined 
treatment and prevention effect among 
serodiscordant partners (ARVs-treatment and 
PrEP/PEP-prevention) at 86% chances of  not 
transmitting and acquiring  HIV vice versa. 
Placing serodiscordant sexual partners in HIV 
treatment and prevention can play a significant 
role in reducing and controlling HIV. 
 
Use of innovative drug dispensing, pharmacy, 
community, national-use of M-health and E-
health systems: Scaling up access from the 
current 16 million ARVs treatment and care to 
over 36-million living with HIV globally, require 
a sustained adoption of test and treat ARVs 
supply-chain management policy which is a 
function of a successful health care system. This 
include innovative strategies that maximise the 
availability and dispensing of drugs. Information 
and communication technology (ICT) including 
digital electronic health (E-Health), messaging 
health (M-Health) and social media at the centre 
of effective health systems support (33). This 
provide and support partners, communities, 
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national, regional and international on effective 
public health services (33). The use of ICT has 
improved partner perception of HIV knowledge in 
many settings (30,31). The dynamism of drug 
automated pharmacy dispensing machines, similar 
working mechanisms as banks automated teller 
machines  (ATM) are key components that can 
reduce HIV structural factors of stigma and 
discrimination while increasing drug uptake,  
retention and adherence in HIV care as well as 
access to HIV drugs which in turn, improve health 
outcomes(21). The use of drug automated 
pharmacy dispensing machines provide 24 hour 
hour access to ARVs and other medications (21). 
Evidence-based studies have highlighted the 
importance of E-Health, M-Health in reducing 
waiting time at health care centres and hospital 
settings (33). The use of M-Health reminds partner 
of medication uptake which has been highly 
associated with sustained viral suppression and 
better health outcomes (32). The use of innovative 
ARVs automated pharmacy dispensing machines 
and holistic integrated pharmacy and community 
drug dispensing system, including national-use of 
ATM medication dispensing could enhance 
innovative strategies in retaining and adhering 
partner in treatment and care. This can 
significantly reduce waiting time in clinical 
settings. However, the lack of ICT operations, 
infrastructures and investment in developing 
countries are limiting factors hindering integrated 
digital health systems (36).  
 
Fostering combination prevention approach: 
Despite the significant role of ARVs, a 
combination approached of behavioural, 
biological and community level engagement are 
additional strategies in containing HIV 
transmission and acquisition (4,9,14,32), each 
contributing a synergic effect. Figure 2 depicts a 
synergic illustration approach of HIV transmission 
and acquisition containment including condom use 
(22), microbicides (23), circumcision(24), 
PMTCT(25), STIs treatment (4,9,14), behavioural 
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HIV treatment/prevention, retention in care and 
adherence are key components of continual 
suppression of HIV (26). The enrolment and 
access to ARVs irrespective of CD4 count and 
access to HIV prevention by HIV negative naïve 
population will reduce HIV transmission and 
acquisition. The model showed a significant 
reduction in HIV incidence. Placing 
serodiscordant sexual partners in HIV treatment 
and prevention can play a significant role in 
reducing and controlling HIV. Therefore, the 
policy of enrolling all HIV positives irrespective 
of CD4 count on ARVs and high risk partners on 
prevention if adopted and sustained may underpin 
reduction and control of HIV genotype. This will 
significantly reduce HIV related morbidity, 
mortality and opportunistic infections. In addition, 
the policy will redefine the future of HIV 
transmission and acquisition as well as access to 
health care services. The use of ICT in changing 
healthcare practice, outcomes and perceptions will 
improve health care accessibility. However, in 
most African settings, ICT operational and 
resources are still at infancy.  
Furthermore, ARVs contextual and 
multifactorial components of HIV risk reduction 
are proactively defined at partner level, 
community, national and public health levels  
(27). Although health system factors including 
long waiting times, drugs supplies, infection 
control, staff attitude and other cross-cutting 
structural elements may affect the acceptability 
and sustained uptake of HCT, ARVs care, viral 
load suppression and HIV prevention strategies 
(37). Programmes with better understanding of 
socio-cultural, economic, demographic and 
structural barriers to HIV treatment may have 
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